Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2994552rdf:typepubmed:Citationlld:pubmed
pubmed-article:2994552lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:2994552lifeskim:mentionsumls-concept:C0162678lld:lifeskim
pubmed-article:2994552lifeskim:mentionsumls-concept:C0681854lld:lifeskim
pubmed-article:2994552lifeskim:mentionsumls-concept:C0027830lld:lifeskim
pubmed-article:2994552lifeskim:mentionsumls-concept:C0001443lld:lifeskim
pubmed-article:2994552lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2994552lifeskim:mentionsumls-concept:C0486805lld:lifeskim
pubmed-article:2994552lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:2994552lifeskim:mentionsumls-concept:C0439596lld:lifeskim
pubmed-article:2994552lifeskim:mentionsumls-concept:C1514485lld:lifeskim
pubmed-article:2994552pubmed:issue1lld:pubmed
pubmed-article:2994552pubmed:dateCreated1985-10-3lld:pubmed
pubmed-article:2994552pubmed:abstractTextSix dermal neurofibromas obtained from 5 patients with neurofibromatosis were dissociated and the cells were plated on polylysine-coated glass. Two principal cell types were observed in the cultures: elongated and bipolar Schwann-like cells (SLCs), and polymorphic flattened fibroblast-like cells (FLCs). Indirect immunofluorescence demonstrated that SLCs expressed surface laminin but not surface fibronectin; FLCs expressed surface fibronectin but were only weakly positive for surface laminin. Tritiated thymidine autoradiography demonstrated that cultured SLCs proliferated slowly (labeling index, 0.7 to 4.0%), whereas FLCs divided more rapidly (labeling index, 7.5 to 26.4%). Axolemmal fragments prepared from human or rat central nervous system specimens adhered to SLCs derived from each of the 6 neurofibromas, but not to FLCs. Axolemmal fragments induced a marked proliferative response of SLCs from 2 of the 6 neurofibromas but had no effect on proliferation of SLCs from the other 4 neurofibromas or FLCs from any of the 6 neurofibromas. In one patient from whom 2 neurofibromas were obtained, SLCs from one neurofibroma responded to axolemmal fragments, while SLCs from the other did not. Treatment of the cultures with 0.1 mM cyclic adenosine 3'5'-monophosphate (cAMP) analogue, 8-bromo cAMP, caused marked inhibition of proliferation of both SLCs and FLCs derived from all 6 neurofibromas. The same concentration of another cAMP analogue, dibutyryl cAMP, inhibited proliferation of SLCs but not of FLCs.lld:pubmed
pubmed-article:2994552pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2994552pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2994552pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2994552pubmed:languageenglld:pubmed
pubmed-article:2994552pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2994552pubmed:citationSubsetIMlld:pubmed
pubmed-article:2994552pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2994552pubmed:statusMEDLINElld:pubmed
pubmed-article:2994552pubmed:monthJullld:pubmed
pubmed-article:2994552pubmed:issn0364-5134lld:pubmed
pubmed-article:2994552pubmed:authorpubmed-author:PleasureDDlld:pubmed
pubmed-article:2994552pubmed:authorpubmed-author:RubensteinA...lld:pubmed
pubmed-article:2994552pubmed:authorpubmed-author:SobueGGlld:pubmed
pubmed-article:2994552pubmed:authorpubmed-author:SonnenfeldKKlld:pubmed
pubmed-article:2994552pubmed:issnTypePrintlld:pubmed
pubmed-article:2994552pubmed:volume18lld:pubmed
pubmed-article:2994552pubmed:ownerNLMlld:pubmed
pubmed-article:2994552pubmed:authorsCompleteYlld:pubmed
pubmed-article:2994552pubmed:pagination68-73lld:pubmed
pubmed-article:2994552pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:meshHeadingpubmed-meshheading:2994552-...lld:pubmed
pubmed-article:2994552pubmed:year1985lld:pubmed
pubmed-article:2994552pubmed:articleTitleTissue culture studies of neurofibromatosis: effects of axolemmal fragments and cyclic adenosine 3',5'-monophosphate analogues on proliferation of Schwann-like and fibroblast-like neurofibroma cells.lld:pubmed
pubmed-article:2994552pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2994552pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2994552pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2994552lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2994552lld:pubmed